GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
GILEAD SCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$153.07−3.12 (-2.00%)
Close on Oct 19, 2026
- Market cap
- $190.27B
- P/E (TTM)
- –
- Dividend yield
- 2.06%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
89.9%
1.11B of 1.24B shares
Institutional holders
2,274
152 new, 164 sold out
Net institutional buying
28M
In Q2 2026
Insider trades, 12 months
0 buys · 75 sales
Net sold $84.72M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vanguard Capital Management | 93,327,127 | 7.51% | 13G (passive) | Mar 31, 2026 |
| FMR LLC | 65,539,477 | 5.30% | 13G (passive) | Dec 31, 2025 |
| Gilead Sciences, Inc. | 18,759,465 | 19.40% | 13G (passive) amendment | Dec 20, 2023 |
| BlackRock, Inc. | 101,739,273 | 8.20% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GILD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 121,844,108 | 9.83% | $15.39B | +2,833,135 | 0.23% |
| Vanguard Capital Management LLC | 81,091,734 | 6.54% | $10.25B | +436,958 | 0.22% |
| FMR LLC | 66,870,816 | 5.39% | $8.45B | −5,035,474 | 0.37% |
| State Street Corp | 61,216,552 | 4.94% | $7.73B | +1,357,967 | 0.23% |
| Capital World Investors | 40,988,975 | 3.31% | $5.18B | −294,958 | 0.61% |
| Invesco Ltd. | 39,819,151 | 3.21% | $5.03B | −1,761,672 | 0.40% |
| Vanguard Portfolio Management LLC | 35,316,168 | 2.85% | $4.46B | +186,703 | 0.20% |
| Geode Capital Management, LLC | 30,065,642 | 2.42% | $3.80B | +339,590 | 0.20% |
| Price T Rowe Associates Inc /Md/ | 29,996,694 | 2.42% | $3.79M | +3,748,586 | 0.38% |
| Morgan Stanley | 24,004,354 | 1.94% | $3.03B | +705,059 | 0.16% |
| Dodge & Cox | 23,677,567 | 1.91% | $2.99B | −573,259 | 1.57% |
| Norges Bank | 21,965,555 | 1.77% | $2.78B | New | 0.28% |
| JPMorgan Chase & Co | 20,820,621 | 1.68% | $2.63B | −13,171,789 | 0.15% |
| Capital Research Global Investors | 19,393,296 | 1.56% | $2.45B | −7,734,237 | 0.34% |
| Bank Of America Corp /De/ | 18,649,065 | 1.50% | $2.36B | −1,329,871 | 0.15% |
| Bank of New York Mellon Corp | 15,263,929 | 1.23% | $1.93B | +210,778 | 0.32% |
| Northern Trust Corp | 13,828,010 | 1.12% | $1.75B | +7,631 | 0.20% |
| UBS Asset Management Americas Inc | 12,986,591 | 1.05% | $1.64B | −212,512 | 0.30% |
| Wellington Management Group Llp | 12,699,683 | 1.02% | $1.60B | −838,308 | 0.28% |
| Goldman Sachs Group Inc | 10,778,294 | 0.87% | $1.36B | −286,920 | 0.12% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2,274 | 1.11B | 89.9% | 152 / 952 | 855 / 164 | 89M | 61M |
| Q1 2026 | 2,325 | 1.09B | 87.9% | 247 / 859 | 897 / 106 | 182M | 93M |
| Q4 2025 | 2,219 | 1.12B | 90.7% | 334 / 879 | 742 / 111 | 130M | 81M |
| Q3 2025 | 2,033 | 1.08B | 87.0% | 166 / 832 | 728 / 126 | 68M | 70M |
| Q2 2025 | 2,026 | 1.08B | 87.3% | 188 / 844 | 732 / 153 | 92M | 73M |
| Q1 2025 | 2,018 | 1.06B | 85.9% | 279 / 690 | 831 / 112 | 91M | 84M |
| Q4 2024 | 1,889 | 1.07B | 85.9% | 291 / 656 | 719 / 94 | 80M | 62M |
| Q3 2024 | 1,722 | 1.05B | 84.8% | 173 / 630 | 697 / 115 | 190M | 63M |
| Q2 2024 | 1,681 | 1.05B | 84.3% | 129 / 650 | 690 / 150 | 58M | 93M |
| Q1 2024 | 1,723 | 1.08B | 87.5% | 139 / 637 | 737 / 170 | 80M | 66M |
| Q4 2023 | 1,779 | 1.07B | 86.4% | 224 / 654 | 696 / 100 | 71M | 39M |
| Q3 2023 | 1,685 | 1.04B | 84.1% | 130 / 686 | 634 / 126 | 38M | 33M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GILD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 39,416,893 | 3.18% | $4.98B | 0.22% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 32,173,750 | 2.59% | $4.06B | 0.24% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 26,355,038 | 2.13% | $3.33B | 0.68% | Jun 30, 2026 |
| Dodge & Cox Stock Fund | 17,282,812 | 1.39% | $2.18B | 1.84% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 17,078,628 | 1.38% | $2.16B | 0.24% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 15,877,011 | 1.28% | $2.13B | 0.26% | May 31, 2026 |
| Income Fund of America | 15,498,550 | 1.25% | $2.02B | 1.36% | Jul 31, 2026 |
| Vanguard Value Index Fund | 11,816,681 | 0.95% | $1.49B | 0.59% | Jun 30, 2026 |
| Fidelity Contrafund | 11,403,513 | 0.92% | $1.44B | 0.80% | Jun 30, 2026 |
| Washington Mutual Investors Fund | 10,310,727 | 0.83% | $1.34B | 0.62% | Jul 31, 2026 |
| American Balanced Fund | 9,637,660 | 0.78% | $1.22B | 0.42% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 8,771,312 | 0.71% | $1.11B | 2.73% | Jun 30, 2026 |
| Capital Income Builder | 8,051,806 | 0.65% | $1.05B | 0.80% | Jul 31, 2026 |
| Vanguard Dividend Appreciation Index Fund | 7,024,740 | 0.57% | $914.69M | 0.70% | Jul 31, 2026 |
| Vanguard Institutional Index Fund | 6,740,120 | 0.54% | $851.55M | 0.24% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel Patrick O'Day | Chairman & CEO, Director | 585,913 | 0.05% | Sep 11, 2026 |
| Erin Burkhart | SVP, Controllership | 2,223 | 0.00% | Sep 23, 2026 |
| Andrew D. Dickinson | Chief Financial Officer | 164,096 | 0.01% | Sep 16, 2026 |
| Johanna Mercier | Chief Comm & Corp Aff Officer | 116,684 | 0.01% | Sep 16, 2026 |
| Wettan Keeley M. Cain | EVP Gen Counsel, Legal & Comp | 8,759 | 0.00% | Sep 11, 2026 |
| Dietmar Berger | Chief Medical Officer | 19,785 | 0.00% | Sep 11, 2026 |
| Deborah H. Telman | EVP, Corporate Affairs & GC | 79,641 | 0.01% | Nov 13, 2025 |
| Diane E. Wilfong | Interim Corp Controller & CAO | 46,597 | 0.00% | Sep 11, 2025 |
| Sandra Patterson | SVP, Controllership | 40,077 | 0.00% | Mar 12, 2025 |
| Merdad Parsey | Chief Medical Officer | 84,621 | 0.01% | Dec 11, 2024 |
| Anthony Welters | Director | 20,612 | 0.00% | Aug 27, 2026 |
| Jeffrey Bluestone | Director | 10,066 | 0.00% | Aug 21, 2026 |
| Kelly A. Kramer | Director | 4,144 | 0.00% | May 4, 2026 |
| Ted W. Love | Director | 5,484 | 0.00% | May 4, 2026 |
| Javier Rodriguez | Director | 13,364 | 0.00% | May 4, 2026 |
| Harish Manwani | Director | 15,015 | 0.00% | May 4, 2026 |
| Jacqueline K. Barton | Director | 27,202 | 0.00% | May 4, 2026 |
| Sandra Horning | Director | 6,293 | 0.00% | May 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Erin Burkhart SVP, Controllership | Sep 22, 2026 | Option exercise | +2,223 | – | – | 2,223 |
| Erin Burkhart SVP, Controllership | Sep 22, 2026 | Tax withholding | −768 | $152.67 | $117.25K | 1,455 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −600 | $145.29 | $87.17K | 116,684 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −800 | $144.46 | $115.57K | 117,284 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −1,600 | $143.69 | $229.90K | 118,084 |
| Andrew D. Dickinson Chief Financial Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −3,000 | $145.29 | $435.87K | 164,096 |
| Dietmar Berger Chief Medical Officer | Sep 10, 2026 | Option exercise | +533 | – | – | 19,785 |
| Dietmar Berger Chief Medical Officer | Sep 10, 2026 | Tax withholding | −263 | $144.81 | $38.09K | 19,522 |
| Daniel Patrick O'Day Chairman & CEO, Director | Sep 10, 2026 | Option exercise | +8,780 | – | – | 585,913 |
| Daniel Patrick O'Day Chairman & CEO, Director | Sep 10, 2026 | Tax withholding | −4,230 | $144.81 | $612.55K | 581,683 |
| Wettan Keeley M. Cain EVP Gen Counsel, Legal & Comp | Sep 10, 2026 | Tax withholding | −285 | $144.81 | $41.27K | 8,759 |
| Wettan Keeley M. Cain EVP Gen Counsel, Legal & Comp | Sep 10, 2026 | Option exercise | +590 | – | – | 9,044 |
| Andrew D. Dickinson Chief Financial Officer | Sep 10, 2026 | Option exercise | +2,797 | – | – | 168,443 |
| Andrew D. Dickinson Chief Financial Officer | Sep 10, 2026 | Tax withholding | −1,347 | $144.81 | $195.06K | 167,096 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Sep 10, 2026 | Tax withholding | −1,347 | $144.81 | $195.06K | 119,684 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Sep 10, 2026 | Option exercise | +2,797 | – | – | 121,031 |
| Daniel Patrick O'Day Chairman & CEO, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −5,408 | $149.38 | $807.85K | 577,133 |
| Daniel Patrick O'Day Chairman & CEO, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −7,992 | $148.36 | $1.19M | 582,541 |
| Daniel Patrick O'Day Chairman & CEO, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −1,600 | $147.51 | $236.02K | 590,533 |
| Anthony Welters Director | Aug 26, 2026 | Option exercise | +7,718 | $60.67 | $468.25K | 20,612 |
| Anthony Welters Director | Aug 26, 2026 | Option exercise | +10,282 | $61.35 | $630.80K | 23,176 |
| Anthony Welters Director | Aug 26, 2026 | Sale(10b5-1 plan) | −3,118 | $148.31 | $462.43K | 17,494 |
| Anthony Welters Director | Aug 26, 2026 | Sale(10b5-1 plan) | −3,402 | $148.24 | $504.31K | 19,774 |
| Anthony Welters Director | Aug 26, 2026 | Sale(10b5-1 plan) | −6,880 | $148.82 | $1.02M | 12,894 |
| Anthony Welters Director | Aug 26, 2026 | Sale(10b5-1 plan) | −4,600 | $148.82 | $684.57K | 12,894 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Sale(10b5-1 plan) | −26 | $146.36 | $3.81K | 10,066 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Option exercise | +335 | $61.35 | $20.55K | 10,401 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Sale(10b5-1 plan) | −335 | $146.26 | $49.00K | 10,066 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Option exercise | +1,816 | $67.45 | $122.49K | 11,882 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Sale(10b5-1 plan) | −1,165 | $143.75 | $167.47K | 10,066 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Option exercise | +1,165 | $67.45 | $78.58K | 11,231 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Sale(10b5-1 plan) | −1,816 | $144.92 | $263.17K | 10,066 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Option exercise | +26 | $67.45 | $1.75K | 10,092 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Sale(10b5-1 plan) | −1,658 | $145.73 | $241.62K | 10,066 |
| Jeffrey Bluestone Director | Aug 20, 2026 | Option exercise | +1,658 | $67.45 | $111.83K | 11,724 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Aug 17, 2026 | Option exercise | +23,110 | $66.64 | $1.54M | 144,344 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Aug 17, 2026 | Option exercise | +1,890 | $72.34 | $136.72K | 146,234 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −16,530 | $137.37 | $2.27M | 129,704 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −11,470 | $138.04 | $1.58M | 118,234 |
| Andrew D. Dickinson Chief Financial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −3,000 | $138.36 | $415.08K | 165,646 |
| Wettan Keeley M. Cain EVP Gen Counsel, Legal & Comp | Aug 10, 2026 | Option exercise | +6,002 | – | – | 11,362 |
| Wettan Keeley M. Cain EVP Gen Counsel, Legal & Comp | Aug 10, 2026 | Tax withholding | −2,908 | $133.06 | $386.94K | 8,454 |
| Daniel Patrick O'Day Chairman & CEO, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −7,700 | $130.80 | $1.01M | 592,733 |
| Daniel Patrick O'Day Chairman & CEO, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −600 | $131.34 | $78.80K | 592,133 |
| Daniel Patrick O'Day Chairman & CEO, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −6,700 | $129.66 | $868.72K | 600,433 |
| Andrew D. Dickinson Chief Financial Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −3,000 | $129.93 | $389.79K | 168,646 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −3,000 | $129.92 | $389.76K | 121,234 |
| Daniel Patrick O'Day Chairman & CEO, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −3,100 | $127.08 | $393.95K | 607,133 |
| Daniel Patrick O'Day Chairman & CEO, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −11,900 | $126.09 | $1.50M | 610,233 |
| Andrew D. Dickinson Chief Financial Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −3,000 | $125.40 | $376.20K | 171,646 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −1,070 | $124.00 | $132.68K | 124,684 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −450 | $125.40 | $56.43K | 124,234 |
| Johanna Mercier Chief Comm & Corp Aff Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −1,480 | $123.42 | $182.66K | 125,754 |
| Daniel Patrick O'Day Chairman & CEO, Director | Jun 10, 2026 | Option exercise | +8,779 | – | – | 626,346 |
| Daniel Patrick O'Day Chairman & CEO, Director | Jun 10, 2026 | Tax withholding | −4,213 | $121.48 | $511.80K | 622,133 |
| Andrew D. Dickinson Chief Financial Officer | Jun 10, 2026 | Option exercise | +2,796 | – | – | 175,987 |
| Andrew D. Dickinson Chief Financial Officer | Jun 10, 2026 | Tax withholding | −1,341 | $121.48 | $162.90K | 174,646 |
| Dietmar Berger Chief Medical Officer | Jun 10, 2026 | Option exercise | +533 | – | – | 19,515 |
| Dietmar Berger Chief Medical Officer | Jun 10, 2026 | Tax withholding | −263 | $121.48 | $31.95K | 19,252 |
| Wettan Keeley M. Cain EVP Gen Counsel, Legal & Comp | Jun 10, 2026 | Option exercise | +589 | – | – | 5,643 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Dickinson Andrew Officer | Oct 15, 2026 | 3,000 | $468.66K | Oct 15, 2026 | Performance Shares |
| Mercier Johanna Officer | Oct 15, 2026 | 3,000 | $468.66K | Oct 15, 2026 | Performance Shares |
| Dickinson Andrew Officer | Sep 15, 2026 | 3,000 | $435.87K | Sep 15, 2026 | Performance Shares |
| Mercier Johanna Officer | Sep 15, 2026 | 3,000 | $432.65K | Sep 15, 2026 | Performance Shares |
| Welters Anthony Director | Aug 26, 2026 | 18,000 | $2.68M | Aug 26, 2026 | Exercise of Stock Options |
| Bluestone Jeffrey Director | Aug 20, 2026 | 5,000 | $738.00K | Aug 20, 2026 | Exercise of Stock Options |
| Mercier Johanna Officer | Aug 17, 2026 | 28,000 | $3.85M | Aug 17, 2026 | Stock Option Exercise |
| Dickinson Andrew Officer | Aug 17, 2026 | 3,000 | $415.08K | Aug 17, 2026 | Performance Shares |
| O'Day Daniel Director, Officer | Aug 3, 2026 | 55,000 | $7.16M | Aug 3, 2026 | Restricted Stock Units and Performance Stock Units |
| Dickinson Andrew Officer | Jul 15, 2026 | 3,000 | $389.78K | Jul 15, 2026 | Performance Shares |
| Mercier Johanna Officer | Jul 15, 2026 | 3,000 | $389.76K | Jul 15, 2026 | Performance Shares |
| Mercier Johanna Officer | Jun 15, 2026 | 3,000 | $371.76K | Jun 15, 2026 | Performance Shares |
| Dickinson Andrew Officer | Jun 15, 2026 | 3,000 | $376.20K | Jun 15, 2026 | Performance Shares |
| O'Day Daniel Director, Officer | Jun 1, 2026 | 35,000 | $4.71M | Jun 1, 2026 | Performance Stock Units |
| Dickinson Andrew Officer | May 15, 2026 | 3,000 | $396.81K | May 15, 2026 | Performance Shares |